Total Valuation
PTC Therapeutics has a market cap or net worth of CHF4.85B. The enterprise value is CHF5.97K.
Market CapCHF4.85B
Enterprise ValueCHF5.97K
Share Statistics
PTC Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders1.47%
Owned by Institutions31.54%
Financial Efficiency
PTC Therapeutics’s return on equity (ROE) is -3.32 and return on invested capital (ROIC) is 33.37%.
Return on Equity (ROE)-3.32
Return on Assets (ROA)0.24
Return on Invested Capital (ROIC)33.37%
Return on Capital Employed (ROCE)0.44
Revenue Per Employee1.75M
Profits Per Employee688.84K
Employee Count991
Asset Turnover0.60
Inventory Turnover0.90
Valuation Ratios
The current PE Ratio of PTC Therapeutics is ―. PTC Therapeutics’s PEG ratio is -0.03.
PE Ratio―
PS Ratio3.49
PB Ratio-29.43
Price to Fair Value-29.43
Price to FCF14.69
Price to Operating Cash Flow-198.33
PEG Ratio-0.03
Income Statement
In the last 12 months, PTC Therapeutics had revenue of 1.73B and earned 682.64M in profits. Earnings per share was 8.58.
Revenue1.73B
Gross Profit1.66B
Operating Income856.51M
Pretax Income696.62M
Net Income682.64M
EBITDA887.66M
Earnings Per Share (EPS)8.58
Cash Flow
In the last 12 months, operating cash flow was -30.50M and capital expenditures -302.05M, giving a free cash flow of -332.56M billion.
Operating Cash Flow-30.50M
Free Cash Flow-332.56M
Free Cash Flow per Share-10.00T>
Dividends & Yields
PTC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
PTC Therapeutics upcoming earnings date is Oct 22, 2026, After Close (Confirmed).
Last Earnings DateJul 30, 2026
Next Earnings DateOct 22, 2026
Ex-Dividend Date―
Financial Position
PTC Therapeutics as a current ratio of 2.35, with Debt / Equity ratio of -421.18%
Current Ratio2.35
Quick Ratio2.27
Debt to Market Cap0.43
Net Debt to EBITDA1.94
Interest Coverage Ratio5.63
Taxes
In the past 12 months, PTC Therapeutics has paid 13.97M in taxes.
Income Tax13.97M
Effective Tax Rate0.02
Enterprise Valuation
PTC Therapeutics EV to EBITDA ratio is 8.75, with an EV/FCF ratio of 18.88.
EV to Sales4.49
EV to EBITDA8.75
EV to Free Cash Flow18.88
EV to Operating Cash Flow10.92
Balance Sheet
PTC Therapeutics has CHF2.23B in cash and marketable securities with CHF696.47M in debt, giving a net cash position of CHF1.53B billion.
Cash & Marketable SecuritiesCHF2.23B
Total DebtCHF696.47M
Net CashCHF1.53B
Net Cash Per ShareCHF10.00T>
Tangible Book Value Per Share-CHF8.50
Margins
Gross margin is 82.14%, with operating margin of 49.49%, and net profit margin of 39.44%.
Gross Margin82.14%
Operating Margin49.49%
Pretax Margin40.25%
Net Profit Margin39.44%
EBITDA Margin51.29%
EBIT Margin49.05%
Analyst Forecast
The average price target for PTC Therapeutics is CHF80.45, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF80.45
Price Target Upside― Upside
Analyst ConsensusModerate Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast―